Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Benitec Biopharma ( (BNTC) ) has provided an announcement.
On November 5, 2025, Benitec Biopharma announced the pricing of a public offering of 5,930,000 shares of common stock and a concurrent registered direct offering of 1,481,481 shares, both priced at $13.50 per share. The offerings, expected to close on November 7, 2025, are projected to raise approximately $100 million in gross proceeds, which Benitec intends to use for the development of its product candidate programs and general corporate purposes. The underwriters, including Leerink Partners, TD Securities, and Evercore ISI, were granted a 30-day option to purchase an additional 889,500 shares. The offerings are part of Benitec’s strategy to strengthen its financial position and support its ongoing research and development efforts.
The most recent analyst rating on (BNTC) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.
Spark’s Take on BNTC Stock
According to Spark, TipRanks’ AI Analyst, BNTC is a Neutral.
Benitec Biopharma’s stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.
To see Spark’s full report on BNTC stock, click here.
More about Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company based in Hayward, California, focused on developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform. This technology, known as ‘Silence and Replace,’ combines RNA interference with gene therapy to create treatments that silence disease-causing genes while delivering replacement genes. The company targets chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Average Trading Volume: 93,373
Technical Sentiment Signal: Sell
Current Market Cap: $414.2M
For detailed information about BNTC stock, go to TipRanks’ Stock Analysis page.